Rising Tide Lifts All BoatsI follow 9 biotech stocks, mostly in Canada. All have gone up considerably since their 2011 lows in the 4th quarter. Only one announced any significant positive news (CUR got an FDA approval). Only two announced negative news (BNC's going-concern clause, YM's dilutive financing). This means the January rise in BNC is not because someone "knows something". Therefore, when BNC gets their financing, we should expect the stock to rise to at least the average of the 9 stocks (+56%) off their lows. This would put BNC at 73 cents. And ANY positive news, such as a global partner etc, would likely move it higher. However, it might not move a lot higher, based on the modest increase CUR showed when they got FDA approval. The big money who pulled out of biotech last April is still sitting on the sidelines.Here is my list:NPC-T: +94%RVX-T: +88%YM-T: +75% (also listed in US) (announced dilutive financing)CUR-T: +55% (FDA approved in Feb/2012)EDAP-Q: +53% (French company listed in US)ICO-V: +48% (TSX Venture exchange)BNC-T: +40% (announced going-concern clause)AEZ-T: +27% (also listed in US)SDI-T: +23% (also listed in US) (conducting buy-back program)-------------------------Arithmetic Average = +56%=========================